In this Monday morning scientific presentation, Dr. Clare Tempany-Afdhal will share findings from a study that evaluated the initial experience, safety, and feasibility of MRgFUS treatment of localized prostate cancer. The research included 36 patients, 32 of whom had prostate lesions and four of whom had none on MRI.
The 32 men with lesions underwent MRgFUS ablation; all except one were discharged on the day of treatment. Six of these 32 have completed follow-up, while 34 are at nine months post-treatment, 27 are at 12 months, and 12 are at 18 months. There were 131 device- or protocol-related adverse advents at the time of MRgFUS treatment: Of these, 117 were mild, 13 were moderate, and one was severe.
The study findings suggest that MRgFUS prostate cancer ablation is both safe and feasible, according to the group.
